Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling

Fig. 7

TNFAIP2 expression positively correlates with NRF2 expression in HNSCC patients. (a-b) Western blot analysis (a) and quantification (b) of TNFAIP2 and NRF2 in 30 pairs of HNSCC tissues (T) and normal tissues (N). (c-d) IHC staining (c) and correlations (d) for TNFAIP2, NRF2, HO1 and NQO1 in the human HNSCC cohort in Fig. 1. (e) Schematic diagram of TNFAIP2 inhibiting ROS/JNK signaling and conferring cisplatin resistance by interacting with KEAP1 and activating NRF2. Scale bars, 100 μm. Data are presented as the mean ± SEM. ** P < 0.01; *** P < 0.001

Back to article page